Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Cipla Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (42)
ARTG (40)
Cancellation or suspension (8)
Prescription medicine registration (6)
Australian public assessment report (AusPar) (3)

Date

(-) 2023 (99)
2026 (9)
2025 (97)
2024 (73)
2022 (70)
2021 (65)
2020 (112)
2019 (18)
2018 (68)
2017 (104)
2016 (27)
2015 (33)
2014 (13)
2013 (6)
2012 (4)
2011 (6)
2010 (16)
2009 (4)
2008 (3)
2007 (5)
2006 (2)
2005 (2)
2004 (2)
2003 (3)
2002 (2)
2001 (3)
2000 (1)
1999 (2)
1998 (1)
1996 (1)

Search

Filters applied:

2023

Clear all

Sponsor content

99 result(s) found, displaying 81 to 90

IBUPAC Ibuprofen Pain Relief ibuprofen 200mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

30 June 2023

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
OPFEX 180 fexofenadine hydrochloride 180mg film coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

30 June 2023

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
APO-SALBUTAMOL salbutamol 5 mg / 2.5mL (as sulfate) inhalation ampoules Cancelled under Section 30(1)(c) of the Act

30 June 2023

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
APO-SALBUTAMOL salbutamol 2.5 mg / 2.5 mL (as sulfate) inhalation ampoules Cancelled under Section 30(1)(c) of the Act

30 June 2023

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
METCIP metformin hydrochloride 500 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

30 June 2023

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
METCIP metformin hydrochloride 850 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

30 June 2023

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
SIMVACOR 80 simvastatin 80 mg tablet bottle Cancelled under Section 30(1)(c) of the Act

30 June 2023

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
SIMVACOR 40 simvastatin 40 mg tablet bottle Cancelled under Section 30(1)(c) of the Act

30 June 2023

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
CIPLA DAPTOMYCIN (Cipla Australia Pty Ltd)

29 June 2023

Prescription medicine registration

Active ingredients: Daptomycin.
AusPAR: Filpegla

22 May 2023

Australian public assessment report (AusPar)

AusPAR for Filpegla (pegfilgrastim) for the treatment of cancer patients following chemotherapy, to decrease the duration of severe neutropenia.

Pages

First page
Previous page
…
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Current page 9
Page 10
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.